Preferential Response of Basal-Like Head and Neck Squamous Cell Carcinoma Cell Lines to EGFR-Targeted Therapy Depending on EREG-Driven Oncogenic Addiction

The management of locally advanced head and neck squamous cell carcinoma (HNSCC) with Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), achieves only moderate response rates, and clinical trials that evaluated EGFR-blockade with tyrosine kinase inhibitors (TKI)...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancers (Basel)
Main Authors: Job, Sylvie, de Reyniès, Aurélien, Heller, Betty, Weiss, Amélie, Guérin, Eric, Macabre, Christine, Ledrappier, Sonia, Bour, Cyril, Wasylyk, Christine, Etienne-Selloum, Nelly, Brino, Laurent, Gaiddon, Christian, Wasylyk, Bohdan, Jung, Alain C.
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6627901/
https://ncbi.nlm.nih.gov/pubmed/31181806
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11060795
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados